24/10/2014 23:34:36 Free Membership Login

Endo, Watson Settle Patent Dispute - Analyst Blog

Date : 06/04/2012 @ 12:38PM
Source : Zacks
Stock : Actavis, Inc. (WPI)
Quote : 85.73  0.0 (0.00%) @ 2:05AM
Watson share price Chart

Endo, Watson Settle Patent Dispute - Analyst Blog

Endo Pharmaceuticals (ENDP) recently announced that it has entered into an agreement to settle two patent infringement lawsuits against Watson Pharmaceuticals (WPI), related to Endo’s lead product, Lidoderm (lidocaine patch 5%).

Although a trial was held on one of these two cases in February 2012, a ruling has yet to come. To mitigate the risk regarding the uncertainty of the court’s decision, the companies mutually decided to resolve the issue.  

Under the terms of the agreement, Watson Pharma will not market a generic version of Lidoderm until the US Food and Drug Administration (FDA) approves Watson Pharma's abbreviated new drug application (ANDA) for its product. If Watson Pharma gains approval before September 15, 2013, the company will not be allowed to launch its product until that day except in certain circumstances.

Meanwhile, Endo will provide $12 million (wholesale acquisition cost) worth of branded Lidoderm product to Watson Pharma every month from January through August 2013. If Watson Pharma fails to gain FDA approval by the end of 2013, Endo will provide $6.67 million worth of branded Lidoderm product per month in 2014 until Watson Pharma gains FDA approval.

In the event of Watson Pharma not gaining approval by the end of 2014, the amount of branded Lidoderm will increase to $7.11 million from January 2015 through September 2015 for each month that Watson Pharma fails to gain FDA approval.

Endo cannot launch an authorized generic unless any company other than Watson Pharma launches generic Lidoderm or for 7.5 months following the launch of Watson Pharma’s product, whichever is earlier.

Watson Pharma is required to pay a royalty of 25% on gross profit during any exclusivity period it may enjoy following the launch of its generic product. The royalty will be payable until another generic including an authorized generic enters the market.

We note that Endo filed an amendment to its Citizen Petition (CP) with the FDA in March 2012. The company has asked the FDA to publicly address concerns regarding the approval requirements for generic versions of Lidoderm. The CP is currently under FDA review.

Lidoderm is used for the relief of pain associated with post herpetic neuralgia (PHN) and generated US sales of $1.2 billion for the twelve months ending March 31, 2012, as per IMS Health Data.

Our Recommendation

We have a Neutral stance on Endo Pharma. The stock carries a Zacks #3 Rank (Hold rating) in the short run.


 
ENDO PHARMACEUT (ENDP): Free Stock Analysis Report
 
WATSON PHARMA (WPI): Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research

Watson (NYSE:WPI)
Historical Stock Chart

1 Year : From Oct 2013 to Oct 2014

Click Here for more Watson Charts.

Watson (NYSE:WPI)
Intraday Stock Chart

Today : Friday 24 October 2014

Click Here for more Watson Charts.


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE and AMEX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

1 site:2 us 141024 23:34